Table 1

Demographics and baseline characteristics

CharacteristicPlaceboIONIS-PTP-1BRx
n3062
Sex, n (%)
 Male16 (53.3)18 (29.0)
 Female14 (46.7)44 (71.0)
Race, n (%)
 Black15 (50.0)34 (54.8)
 White12 (40.0)18 (29.0)
 Asian1 (3.3)6 (9.7)
 Other2 (6.7)4 (6.5)
Age (years), mean (SD)57.3 (7.3)56.4 (8.6)
BMI (kg/m2), mean (SD)35.1 (5.8)34.1 (5.5)
OAD therapy, n (%)
 Metformin30 (100.0)62 (100.0)
 Sulfonylurea14 (46.7)37 (59.7)
  Gliclazide8 (26.7)21 (33.9)
  Glibenclamide4 (13.3)14 (22.6)
  Glimepiride2 (6.7)2 (3.2)
Full analysis set, n*2961
Fasting glucose (mg/dL), mean (SD)183.1 (38.2)171.2 (40.8)
HbA1c (%), mean (SD)8.6 (1.0)8.7 (1.0)
HbA1c (mmol/mol), mean (SD)70 (10.9)72 (10.9)
  • *Includes all patients in safety population who had a valid baseline and at least one postbaseline HbA1c measurement.